Plné znění - 2/2008 Sb. m. s.

Ministerstvo xxxxxxxxxxxx xxxx sděluje, xx xxx 16. listopadu 2007 xxxx xxxxxxxxxx xxxxxxxxx UNESCO, depozitářem Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx.

Xxxxxxx X vstoupila x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2008 x tímto xxxx xxxxxxxxx x xxxxxxxx i xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx Přílohy X x xxxxxxxx xxxxxxxx xxxxxx Příloha X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xx znění pro xxx 2007, xxxxxxxxx xxx x. 59/2007 Xx. x. x.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého xxxxxx xx vyhlašují xxxxxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

x. Xxxxxxxx * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); bolasteron; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); methyl-1-testosteron (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); methyltestosteron; xxxxxxxxx; nandrolon; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); norboleton; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-testosteron (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

x. Xxxxxxxxx ** XXX:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-androstan-3β,17α-diol 5-androstendion (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17β-xxxx

V xxxxxxxxx, xxx xxxx xxxx produkovat androgenní xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx xxx xx to, že Xxxxxx obsahuje xxxx Xxxxxxxxx xxxxx x xxxx xxxxxx pozitivní Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx látky nebo xxxxxx metabolitů xxxx xxxxxxxxxxx x/xxxx xxxx xx xxxxxxxx xxxx xxxxxxxxx poměr ve Xxxxxx Sportovce xxxxxxxx xxxxxxxxx xx rozmezí xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx u xxxx tak, že xxxxxxxxxx xxxxxxxx endogenní xxxxxxxx. Xxxxxx se xxx xx to, xx Xxxxxx xxxxxxxx Xxxxxxxxx látku v xxxxxxx případě, xxxxx Xxxxxxxxx xxxxxxx, že xx koncentrace Zakázané xxxxx nebo xxxxxx xxxxxxxxxx nebo xxxxxxxxxx x/xxxx xxxxxxxxx xxxxx xx Vzorku Xxxxxxxxx xxxxxxxx fyziologickým xxxx xxxxxxxxxxxx stavem.

Bude xx xxx xx xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx xx xxxxx xxxxxxxxx a xxx xxxxxxxxx koncentraci, xxxxx xxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, xx xx Zakázaná látka xxxxxxxxxx xxxxxx. V xxxxxxx xxxxxxx xxxx xxxxx provádět xxxxx xxxxxxx.

Xxxx xx xxxxxxx xxxxxxxx analýzy xxxxxxxx neodchylují od xxxxxxx hodnot, xxxxx xx xxxxxxxx vyskytují x lidí x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, ale xxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky, xxxx xxxx. porovnání x xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxx X/X vyšší xxx xxxxx (4) xx xxxxx (1) x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, provede příslušná Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx výsledků xxxxxxxxxx testů xxxx xxxxxxxxxx xxxxxxxxxx xxxxx.

Xx-xx xxxxxxxxxx xxxxxx xxxxx xxxxxxx, pak xxxxxxxx bude xxxxxxxxxx xxxxxx jako neobvyklý x xx xxxx xxxxxxxxx. Pokud laboratoř xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) exogenní xxxxx Xxxxxxxx xxxxx, xxxx xxxxx provádět xxxxx šetření, x xxxx xx xxx xx to, že Xxxxxx obsahuje Zakázanou xxxxx. Pokud nebyla xxxxxxx spolehlivá xxxxxxxxxx xxxxxx (xxxx. IRMS) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx tím, xx xxxx příslušnou Xxxxxxxxxxxxxx xxxxxxxxxx v následujících 3 xxxxxxxx třikrát xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, xxxxx xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, xxxx xxxxxx xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx xxxxxxxxxxxx xxxxxxxx, xxxx xx xxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx.

X xxxxxxxx xxxxxxxx individuálních xxxxxxxxx xxxx xxx x moči trvale xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx velice xxxxxx koncentracích (xx/xx). Xxxxx xxxxxxxxx takový xxxxx xxxxxxxxx a xxxxxxx spolehlivé analytické xxxxxx (např. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, může xxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx následného xxxxx (xxxxxxxxxx testů).

Xxxxx laboratoř nahlásila Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, xxxx xx xx xxxxxxxxx xx xxxxxxx x přesvědčivý xxxxx xxxxxxxxxx xxxxxx Xxxxxxxx xxxxx. X xxxxxxx případě xxxx xxxxx xxxxxxxx xxxxx xxxxxxx.

V xxxxxxx, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx při xxxxxxx xxxxxxxxx, xxxx se xxx xx xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:

Xxxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, zilpaterol, xxx xx s xxxxxxxx xxxxx xx ně.

S2. XXXXXXX X PŘÍBUZNÉ XXXXX

Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (EPO);

2. Růstový xxxxxx (xXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxxx (xxxx. XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (např. LH, xXX), zakázané xxx x mužů;

4. Xxxxxxxx;

5. Kortikotropiny

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx xxxxxx prokázat, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxx, xxxx xx xxx za xx, že Vzorek xxxxxxxx Xxxxxxxxx xxxxx (xxx je xxxxxxx xxxx) x xxxxxxxxx, xxx xxxxxxxxxxx Zakázané xxxxx xxxx xxxxxx xxxxxxxxxx či xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Xxxxxx Sportovce xxxxxxx xxxxxxxx hodnoty xxxxxxxx xxxxxxxx x xxxx xxx, xx xxxxxxxxxxxx normální endogenní xxxxxxxx.

Xxxxx xxxxxxxxx xxxxxxxxx, xx xxxxx xxxxxxxxxx analytické xxxxxx, xx Xxxxxxxx xxxxx xx exogenního xxxxxx, xxxx xx mít xx xx, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx a bude xxxxxxx Pozitivní xxxxxxxxxxx xxxxx.

X3. XXXX-2 XXXXXXXX

Všichni xxxx-2 xxxxxxxx xxxxxx xxxxxx D- x X-xxxxxxx jsou zakázáni.

Xxxxxxxx jsou formoterol, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, xxx xxxxx xx xxx xxxxxxxx xxxxx udělení xxxxxxxx xxxxxxxxxxxx xxxxxxx.

I xxxx xxxx xxxxxxx xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx xxxxx xxxxxxxxxxx (xxxxx xxxx xxxxxxxxxx) xxxxx xxx 1000 xxxxxxxxx x 1 xxxxxxxxx moči xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxx.

X4. XXXXXXXXXXX X MODULÁTORY HORMONŮ

Xxxxxxxxxxx skupiny jsou xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, zahrnující:

2. Xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne x omezením pouze xx xx.

X5. DIURETIKA A XXXXXXX XXXXXXXXX LÁTKY

Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx alfa-reduktázy (např. xxxxxxxxxx, dutasterid), xxxxxxxxxxxxxxx (xxxx. xxxxxxx, xxxxxxx, xxxxxxxxxxxxxxxxx) a další xxxxx x podobnými xxxxxxxxxxxx účinky.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, metolazon, spironolakton, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxx není xxxxxxxx).

* Terapeutická xxxxxxx xxxx platná, xxxxx moč Xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxx x prahovou xxxx xxxxxxxxxxx hladinou xxxx Xxxxxxxx xxxxx (xxxxx).

X1. ZVYŠOVÁNÍ PŘENOSU XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

X3. XXXXXX DOPING

Neterapeutické xxxxxxx xxxxx, xxxx, xxxxxxxx elementů, xxxx xxxxxxxxxx exprese genů, xxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxx.

X6. XXXXXXXXXXX

Všechna xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx optických (X- x X-) xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx derivátů xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxx x stimulancií xxxxxxxxxx xx Monitorovacího programu xxx xxx 2008.

Xxxxxxxxxxx zahrnují:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, amfetamin, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, cyklazodon, xxxxxxxxxxxxxxxxx, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, famprofazon, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxx***, klobenzorex, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), metylefedrin****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, methylfenidát, xxxxxxxx, xxxxxxxxx, niketamid, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxx, propylhexedrin, xxxxxxxxx, xxxxxxxxxx, strychnin, xxxxxxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx příklady x xxxxx oddíle bude xxxxxxxxxx xx xxxxxxxxxxx xxxxx pouze, pokud Xxxxxxxxx xxxxxxx, xx xxxx xxxxxxxxx xxxxxxxxxx x běžných xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxx xx u xxx xxxxx xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx jako xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Následující xxxxxxxxx xxxx zakázaná:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, oxymorfon, pentazocin, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, marihuana) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx glukokortikosteroidy xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx zakázané. Xxxxxx užití xxxxxxxx xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx xxxxxxxx aplikace (xxxxxxxxxxxx, xx xxxxx xxxxxx, xx okolí xxxxxx, xxxxxxxxxx, xx xxxx) a xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxx výjimku x xxxxxxxx xxxx uvedených.

Xxxxxxx xxxxxxxxx podávané xx potíže xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), xxxx, xxxxx, xxxx, potíže xxxxx xxxxxxx xxxxxx, xxxxxxxx xxx x xxxxx nejsou xxxxxxxx x xxxxxxxxxx žádnou xxxxx xxxxxxxxxxxx xxxxxxx.

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx xxx porušení xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je xxx xxxxxx xxxxxxxx uvedena x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 g/l)

∙ Xxxxxx (XXX) (0.10 x/x)

∙ Letecké xxxxxx x xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Xxxxxxxxxxx (XXXX, XXX) (0.10 x/x)

∙ Xxxxxxx xxxxxxx (XXXX) xxx pro xxxxxxxxxx se xxxxxxxx (0.10 x/x)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Xxxxx motorismus (XXX) (0.30 x/x)

∙ Kuželky (IPC) (0.10 x/x)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx soutěži x xxxxxxxxxxxxx sportech.

∙ Xxxxxxxxxxxx xxxxx (XXX)

∙ Billiard (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Curling (XXX)

∙ Gymnastika (XXX)

∙ Xxxxxxxx (XXXX) - "xxxxx xxxx" - xxx xxxxxxxxxxx

∙ Kuželky (XXX)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x akrobatické xxxxxxxx-xxxxx a X-xxxxx, x snowboard X-xxxxx x "xxx xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx xx xxxxxxxx

∙ Xxxxxxxxxxx sport (XXX)

∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX, XXX "xxxxx")

∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)

∙ Xxxxx xxxxxxxxxx (UIM)

∙ Xxxxx (FILA)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, celiprolol, esmolol, xxxxxxxxx, karvedilol, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx ne x xxxxxxxx xxxxx na xx

"Specifické xxxxx"* xxxx vyjmenovány xxxx:

∙ Xxxxxxx Xxxx-2 xxxxxxxx x inhalaci, xxxxx xxxxxxxxxxx (volného xxxx glukuronidu) xxx xxxxxxxx xxxxxx xxx 1000 ng/ml xxxx x xxxxxxxxxxxx (zařazen xx skupině S 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, kropropamid, krotetamid, xxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx a všechna xxxxxxx stimulancia xxxxxxxxx xxxxxxxx x xxxxxx X6, xxx xxxxx Xxxxxxxxx prokáže, xx xxxxxxx xxxxxxxx popsané x xxxxxx X6;

∙ Kanabinoidy;

∙ Xxxxxxx Glukokortikosteroidy;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx xxx vyjmenovány xxxxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx antidopingových xxxxxxxx, xxxxxxx xxxx všeobecně xxxxxxxx x xxxxxxx xxxxxxxxx xxxxxxxxxxx, xxxx x xxxxx je xxxxx xxxxxxxxxxxxxxx, xx xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx činidla." Xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx takovéto látky xxxx xxxxxxxx xxxxxxx xxxxxx za předpokladu, xx "...Xxxxxxxxx xxxx xxxxx xxxxxxxx, xx Xxxxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx předpis č. 2/2008 Sb. m. x. xxxxx xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. xxx xxxxxx xxxxxxx předpisem č. 8/2009 Sb. m. s. x xxxxxxxxx od 7.2.2009.

Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.